Document:

ex102lgndcormatrixarinte

Execution   US-DOCS\85889051.6         AMENDED AND RESTATED INTEREST PURCHASE AGREEMENT dated as of  May 31, 2017, between CORMATRIX CARDIOVASCULAR, INC. and LIGAND PHARMACEUTICALS INCORPORATED             

 

  US-DOCS\85889051.6 TABLE OF CONTENTS Page ARTICLE I  Definitions SECTION 1.01.   Defined Terms .................................................................................................. 1 ARTICLE II  Purchase of Assigned Interests SECTION 2.01.   Purchase ............................................................................................................ 9 SECTION 2.02.   Payments by the Company................................................................................ 9 SECTION 2.03.   Closing; Payment of Purchase Price; Deliveries .............................................. 10 SECTION 2.04.   No Assumed Obligations; Acquisition of Assigned Interests Alone ................ 10 ARTICLE III  Representations and Warranties of the Company SECTION 3.01.   Organization ...................................................................................................... 11 SECTION 3.02.   Authorization .................................................................................................... 11 SECTION 3.03.   Governmental Authorization ............................................................................ 11 SECTION 3.04.   Ownership ......................................................................................................... 11 SECTION 3.05.   Litigation ........................................................................................................... 12 SECTION 3.06.   Compliance with Laws ..................................................................................... 12 SECTION 3.07.   Conflicts ............................................................................................................ 12 SECTION 3.08.   Current Indebtedness ........................................................................................ 13 SECTION 3.09.   Solvency ............................................................................................................ 13 SECTION 3.10.   Financial Statements ......................................................................................... 13 SECTION 3.11.   Products............................................................................................................. 13 ARTICLE IV  Representations and Warranties of Purchaser SECTION 4.01.   Organization ...................................................................................................... 13 SECTION 4.02.   Authorization .................................................................................................... 13 SECTION 4.03.   Conflicts ............................................................................................................ 14 ARTICLE V  Covenants SECTION 5.01.   Access; Information .......................................................................................... 14 SECTION 5.02.   Confidentiality; Press Release .......................................................................... 15 

 

ii  US-DOCS\85889051.6 SECTION 5.03.   Efforts; Further Assurance ................................................................................ 16 SECTION 5.04.   Licenses............................................................................................................. 16 SECTION 5.05.   Remedies Event ................................................................................................ 16 SECTION 5.06.   Diligence ........................................................................................................... 16 SECTION 5.07.   Indebtedness; Sale of Revenue Interests ........................................................... 16 ARTICLE VI  Termination SECTION 6.01.   Termination ....................................................................................................... 17 SECTION 6.02.   Effect of Termination ........................................................................................ 17 ARTICLE VII  Miscellaneous SECTION 7.01.   Survival ............................................................................................................. 17 SECTION 7.02.   Notices .............................................................................................................. 17 SECTION 7.03.   Successors and Assigns..................................................................................... 18 SECTION 7.04.   Indemnification ................................................................................................. 19 SECTION 7.05.   No Implied Representations and Warranties .................................................... 20 SECTION 7.06.   Independent Nature of Relationship ................................................................. 20 SECTION 7.07.   Entire Agreement .............................................................................................. 21 SECTION 7.08.   Amendments; No Waivers ................................................................................ 21 SECTION 7.09.   Interpretation ..................................................................................................... 21 SECTION 7.10.   Headings and Captions ..................................................................................... 21 SECTION 7.11.   Counterparts; Effectiveness .............................................................................. 22 SECTION 7.12.   Severability ....................................................................................................... 22 SECTION 7.13.   Expenses ........................................................................................................... 22 SECTION 7.14.   Governing Law; Jurisdiction............................................................................. 22 ARTICLE VIII  Intercreditor Matters SECTION 8.01.   Purchase and Sale Treatment; Recharacterization ............................................ 22 SECTION 8.02.      Other Purchaser Security .................................................................................. 23 SECTION 8.03.      Priority .............................................................................................................. 24 SECTION 8.04.    Control Agreements ............................................................................................ 24 SECTION 8.05.     Termination or Release ...................................................................................... 24 ARTICLE IX  Remedies SECTION 9.01.   Remedies ........................................................................................................... 25  

 

  US-DOCS\85889051.6 This AMENDED AND RESTATED INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of May 31, 2017 (the “Effective Date”), by and between CORMATRIX CARDIOVASCULAR, INC., a Georgia corporation (the “Company”), and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (“Purchaser”). RECITALS WHEREAS, the Company and the Purchaser previously entered into that certain Interest Purchase Agreement dated as of May 3, 2016 (the “Prior Agreement”); WHEREAS, on the date hereof, the Company is entering into an asset purchase agreement with Aziyo Biologics, Inc., a Delaware corporate (“Parent”) and Aziyo Med, LLC, a Delaware limited liability company and wholly-owned subsidiary of Parent (“Aziyo”) pursuant to which the Company is selling certain assets related to the Base Products and the CanGaroo Products (as such terms are defined in the Prior Agreement) (the “Asset Purchase Agreement”); WHEREAS, in connection with the Asset Purchase Agreement, Aziyo and the Purchaser are entering into that certain royalty agreement, dated as of the date hereof, with respect to the Base Products and CanGaroo Products (the “Aziyo Royalty Agreement”); WHEREAS, Aziyo will repay in full the Company’s outstanding debt with MidCap Financial SBIC LP, a Delaware limited partnership, at the closing of the sale of such assets; and  WHEREAS, the Company and the Purchaser desire to amend and restate the Prior Agreement, as set forth herein; NOW, THEREFORE, in consideration of the mutual covenants, agreements and representations and warranties set forth herein, the parties hereto agree as follows: ARTICLE I  Definitions SECTION 1.01.  Defined Terms.  As used in the Agreement, the following terms shall have the meanings specified below: “Acquiror” shall mean, with respect any of the Products, any Person (other than any Affiliate of the Company) who acquires control of the commercialization of any such Product as a result of any Product Change of Control. “Affiliate” shall mean any Person that controls, is controlled by, or is under common control with another Person.  For purposes of this definition, “control” shall mean 

 

2  US-DOCS\85889051.6 (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. “Assigned Interest Period” shall mean, with respect to each Product, the period from and including the Effective Date through and including the date that is the tenth anniversary of the date of the first commercial sale of such Product.  “Assigned Interest Related Collateral” means any accounts (as defined in Article 9 of the UCC) giving rise to the Assigned Interests and the proceeds of such accounts. “Assigned Interests” shall mean the Pipeline Product Interests and the Valves Product Interests. “Audit Costs” shall mean, with respect to any audit of the books and records of the Company or its Subsidiaries with respect to amounts payable or paid under this Agreement, the reasonable out-of-pocket cost of such audit, including all fees, costs and expenses incurred in connection therewith. “Bankruptcy Event” shall mean the occurrence of any proceeding being instituted by or against the Company seeking to adjudicate it bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of it or its debts under any law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking the entry of an order for relief or the appointment of a receiver, trustee or other similar official for it or any substantial part of its property, or the Company taking any action to authorize any of the actions set forth above.  Notwithstanding the foregoing, if such proceeding is instituted against the Company, no Bankruptcy Event shall have occurred unless such proceeding remains undismissed, undischarged or unbonded for a period of sixty (60) days.  “Books” shall mean all of the books and records of a Person, including ledgers, federal and state tax returns, records regarding the Person’s assets or liabilities, the Assigned Interest Related Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. “Business Day” shall mean any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of New York, or any day on which banking institutions located in the State of New York are required by law or other governmental action to close. “Closing” shall have the meaning set forth in Section 2.03(a). “Closing Date” shall mean May 3, 2016. “Company” shall have the meaning set forth in the preamble. 

 

3  US-DOCS\85889051.6 “Company Change of Control” shall mean, with respect to the Company: (a) the acquisition by any Person or group (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of beneficial ownership of any capital stock of the Company, if after such acquisition, such Person or group would be the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended, but assuming that any convertible securities owned by such Person or group or any controlled affiliates thereof are immediately exercisable), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors; (b) a merger or consolidation of the Company, with any other Person, other than a merger or consolidation which would result in the Company’s voting securities outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of the Company’s voting securities or such surviving entity’s voting securities outstanding immediately after such merger or consolidation; or (c) the bona fide sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any of its Subsidiaries of all or substantially all the assets of the Company and its Subsidiaries, taken as a whole. “Confidential Information” shall mean, as it relates to the Company and its Affiliates and any of the Products, the Intellectual Property related to any of the Products, confidential business information, financial data and other like information (including ideas, research and development, know-how, formulas, schematics, compositions, technical data, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), inventory, ideas, algorithms, processes, computer software programs or applications (in both source code and object code form), client lists and tangible or intangible proprietary information or material, or such other information that either party identifies to the other as confidential or the nature of which or the circumstances of the disclosure of which would reasonably indicate that such information is confidential.   Notwithstanding the foregoing definition, Confidential Information shall not include information that (a) is already in the public domain at the time the information is disclosed, (b) thereafter becomes lawfully obtainable from other sources who, to the knowledge of the recipient, have no obligation of confidentiality, (c) can be shown to have been independently developed by the recipient or its representatives without reference to any Confidential Information of the other party or (d) is required to be disclosed under laws, rules and regulations of any Governmental Authority applicable to the Company or its Affiliates or Purchaser or its Affiliates, as the case may be, or pursuant to the rules and regulations of any securities exchange or trading system or pursuant to any other laws, rules or regulations of any Governmental Authority having jurisdiction over the Company and its Affiliates or Purchaser and its Affiliates. 

 

4  US-DOCS\85889051.6  “Excluded Costs” shall mean the following items to the extent permitted by generally accepted accounting principles: (i) value added or any other similar transaction taxes accrued on sales invoices, (ii) sales discounts and all kinds of rebates, (iii) any orders or parts thereof which are subsequently returned to the Company (or an Affiliate, agent or sublicensee thereof, as applicable) and refunded to the customer or wholesaler, (iv) charges for late payment collected from customers, registration charges and other service charges and (v) applicable shipping charges. “Excluded Liabilities and Obligations” shall have the meaning set forth in Section 2.04(a). “Final Order” shall mean an order of the United States Bankruptcy Court or any other court of competent jurisdiction as to which the time to appeal, petition for certiorari, or move for reargument or rehearing has expired and a to which non appeal, petition for certiorari, or other proceedings for reargument or rehearing shall then be pending, or, in the event that an appeal, writ of certiorari, or reargument or rehearing thereof has been filed or sought, such order of the Bankruptcy Court or other court of competent jurisdiction shall have been affirmed by the highest court to which such order was appealed, or from which certiorari, reargument or rehearing was sought, and the time to take any further appeal, petition for certiorari or move for reargument or rehearing shall have expired; provided that the possibility that a motion under Rule 59 or Rule 60 of the Federal Rules of Civil Procedure or any analogous rule under the Federal Rules of Bankruptcy Procedure or applicable state court rules of civil procedure, may be filed with respect to such order shall not cause such order not to be a Final Order.  “Fiscal Quarter” shall mean each three (3) month period commencing January 1, April 1, July 1 or October 1, provided however that (a) the first Fiscal Quarter of the Term shall extend from the Closing Date to the end of the first full Fiscal Quarter thereafter and (b) the last Fiscal Quarter of the Term shall end upon the expiration or termination of this Agreement. “Fiscal Year” shall mean the calendar year. “Governmental Authority” shall mean any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state or local (domestic or foreign). “Intellectual Property” shall mean all proprietary information; technical data; laboratory notebooks; clinical data; priority rights; trade secrets; know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application); Patents; registered or unregistered trademarks, trade names, service marks, including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned, controlled by, generated by, issued to, licensed to, licensed by or hereafter acquired by or licensed by the Company or its Subsidiaries. 

 

5  US-DOCS\85889051.6 “Knowledge of the Company” shall mean the current and actual knowledge, information or belief held by David B. Camp, Robert G. Matheny, John C. Thomas, Jr. and/or Andrew M. Green after reasonable inquiry by such person into the relevant subject matter.  “Losses” shall mean collectively, any and all claims, damages, losses, judgments, awards, penalties, liabilities, costs and expenses (including reasonable expenses and reasonable attorneys’ fees) incurred in connection with defending any action, suit or proceeding.  “Material Adverse Change” shall mean, with respect to the Company and its Subsidiaries, any event, change, circumstance, occurrence, effect or state of facts that has caused or is reasonably likely to cause a material adverse change in the business, operations, assets or financial condition of the Company and its Subsidiaries, taken as a whole. “Material Adverse Effect” shall mean (a) the effect of a Material Adverse Change, (b) a material adverse effect on the validity or enforceability of this Agreement, (c) the inability or failure of the Company to make payments in respect of the Assigned Interests in violation of this Agreement, (d) a material adverse effect on the ability of the Company to perform any of its other material obligations under this Agreement or (e) any material adverse effect on the Products or the ability of the Company and its Subsidiaries to distribute, market and/or sell the Products. “MidCap Payoff Letter” shall mean the letter from MidCap evidencing payment in full of the MidCap Credit Facility, dated as of the date hereof. “MidCap Credit Facility” shall mean that certain Credit and Security Agreement, dated as of June 10, 2014 (as amended, amended and restated, supplemented or otherwise modified as of the date hereof), among CorMatrix Cardiovascular, Inc., CorMatrix RE LLC, CorMatrix 1 LLC and CorMatrix 2 LLC, as Borrowers (as defined therein), MidCap Financial Trust, a Delaware statutory trust, as administrative agent, and the Lenders (as defined therein) party thereto.      “Monthly Report” shall mean, with respect to the relevant Payment Month of the Company, a report showing (a) the gross revenues of the Pipeline Products and Valves Products for such Payment Month, (b) the Pipeline Product Net Sales and the Valves Product Net Sales for such Payment Month, (c) the Excluded Costs for such Payment Month and (d) a reasonable calculation of the amount to which Purchaser is entitled for such Payment Month pursuant to Section 2.02(a) of this Agreement. “Obligations” shall mean any and all payment obligations of the Company under the Agreement.  “Parties” shall mean Purchaser, the Company and any other Person from time to time made party to this Agreement, each a “Party.” 

 

6  US-DOCS\85889051.6 “Patent” shall mean all patents, patent rights, patent applications, patent disclosures and invention disclosures issued or filed, together with all reissues, divisions, continuations, revisions, term extensions, substitutes, supplementary protection certificates, reexaminations, inter-partes reviews, post-grant oppositions or similar post-grant review proceedings, including the inventions claimed in any of the foregoing and any priority rights arising therefrom, that are issued or filed as of the date hereof or during the Term, which are owned by the Company, its Subsidiaries or any of its Affiliates. “Payment Month” shall mean each month-long period commencing on the first day of such month, provided however that (a) the first Payment Month of the Term shall extend from the Closing Date to the end of the first full Payment Month thereafter and (b) the last Payment Month of the Term shall end upon the expiration or termination of this Agreement. “Permitted Transaction” shall mean any transaction during the Term whereby the Company incurs, creates, assumes or permits to exist any indebtedness for borrowed money or sells, assigns, transfers or conveys any Revenue Interests to any Third Party; provided that such transaction (a) does not, except to the extent expressly contemplated by Section 8.04, result in any security interest granted hereunder ceasing to be a valid and perfected security interest or adversely affecting the priority of such interest and (b) could not reasonably be expected to impair the ability of the Company to comply with the requirements to make the payments set forth in Section 2.02.  “Person” shall mean an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, but not including a government or political subdivision or any agency or instrumentality of such government or political subdivision. “Pipeline Product Applicable Percentage” shall mean 5% with respect to any Pipeline Product Net Sales during the Assigned Interest Period. “Pipeline Product Interests” shall mean the right to receive on a monthly basis cash in an amount equal to the product of the Pipeline Product Applicable Percentage multiplied by the Pipeline Product Net Sales during the Assigned Interest Period, pursuant to the terms and conditions of this Agreement.  For the avoidance of doubt, Pipeline Product Interests shall not constitute any accounts or payment intangibles (as each term is defined in the UCC) giving rise to such cash amounts. “Pipeline Product Net Sales” shall mean the aggregate amount of sales proceeds received by the Company (or an Affiliate, agent or sublicensee thereof, as applicable) for the Pipeline Products sold on or after the Closing Date, less Excluded Costs. “Pipeline Products” shall mean the following extracellular matrix technology products, in each case, sold by the Company: (i) the Micronized ECM product, (ii) the Epicardial Infarction Repair product, (iii) the Vascular Graft product, (iv) any other products that were in development as of the Closing Date, and (v) any product substantially 

 

7  US-DOCS\85889051.6 similar in design and application to any product described in the foregoing clauses commercialized by the Company during the Assigned Interest Period.   “Prior Agreement” shall have the meaning set forth in the recitals. “Product Change of Control” shall mean, with respect to any Product, or any product enumerated in the definition of any Product (or in any Schedule referenced in any such definition), any sale or other transfer by the Company of substantially all of the assets primarily used to commercialize such Product or such enumerated product or of the exclusive right to commercialize such Product or such enumerated product. “Products” shall mean the Pipeline Products and the Valves Products. “Purchase Price” shall mean $17,500,000. “Purchaser” shall have the meaning set forth in the preamble. “Purchaser Account” shall mean the following account (or such other account as Purchaser may designate in writing (such designation to be made at least two (2) Business Days prior to any payment owing to Purchaser under this Agreement)): Ligand Pharmaceuticals, Inc. Bank of America Merrill Lynch Account No. 1453127240 Routing No. 026009593  “Recharacterization” shall mean a characterization by a Final Order of the United Stated Bankruptcy Court or any other court of competent jurisdiction of the purchase of the Assigned Interests as a loan or other financing instrument or that the Purchaser does not have an ownership interest in the Assigned Interests. “Regulatory Agency” shall mean a Governmental Authority with responsibility for the approval of the marketing and sale of surgical implants or other regulation of surgical implants. “Regulatory Approvals” shall mean all approvals (including, without limitation, where applicable, pricing and reimbursement approval and schedule classifications), product and/or establishment licenses, registrations or authorizations of any Governmental Authority necessary for the manufacture, use, storage, import, export, transport, offer for sale, or sale of any of the Products. “Remedies Event” shall mean (a) a Bankruptcy Event or (b) a failure by the Company to make a payment pursuant to Section 2.02, provided that no such failure shall constitute a Remedies Event unless such failure shall remain uncured for thirty (30) days. “Revenue Interests” shall mean all of the interest of the Company and its Subsidiaries in the proceeds of the total sales realized by the Company (or an Affiliate, 

 

8  US-DOCS\85889051.6 agent or sublicensee thereof, as applicable) of the Products sold on or after the Effective Date. “SEC” shall mean the U.S. Securities and Exchange Commission. “Special Account” shall have the meaning set forth in Section 8.03(b). “Subsidiary” shall mean, with respect to any Person, a corporation, partnership, joint venture, limited liability company or other business entity of which (i) a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, (ii) more than half of the issued share capital is at the time beneficially owned or (iii) the management of which is otherwise controlled, directly or indirectly, through one or more intermediaries, or both, by such Person.   “Term” shall have the meaning set forth in Section 6.01. “Third Party” shall mean any Person other than Purchaser and any Affiliate of Purchaser or the Company and any Subsidiary of the Company. “Transfer” shall have the meaning set forth in Section 8.05. “UCC” shall mean the Uniform Commercial Code as in effect in the State of New York from time to time. “Valves Product Applicable Percentage” shall mean 5% with respect to any Valves Product Net Sales during the Assigned Interest Period. “Valves Product Interests” shall mean the right to receive on a monthly basis cash in an amount equal to the product of the Valves Product Applicable Percentage multiplied by the Valves Product Net Sales during the Assigned Interest Period, pursuant to the terms and conditions of this Agreement. For the avoidance of doubt, Valves Product Interests shall not constitute any accounts or payment intangibles (as each term is defined in the UCC) giving rise to such cash amounts.  “Valves Product Net Sales” shall mean the aggregate amount of sales proceeds received by the Company (or an Affiliate, agent or sublicensee thereof, as applicable) for the Valves Products sold on or after the Closing Date, less Excluded Costs. “Valves Products” shall mean the extracellular matrix technology products sold by the Company for the remodeling, repair or replacement of the tricuspid, pulmonary, mitral or aortic valves and any product substantially similar in design and application to any such product commercialized by the Company during the Assigned Interest Period.  

 

9  US-DOCS\85889051.6 ARTICLE II  Purchase of Assigned Interests SECTION 2.01.  Purchase.  Upon the terms and subject to the conditions set forth in this Agreement, the Company previously sold, assigned, transferred and conveyed to Purchaser, and Purchaser purchased from the Company, free and clear of all liens (except any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable), all of the Company’s rights and interests in and to the Assigned Interests on the Closing Date.  Purchaser’s ownership interest in the Assigned Interests so acquired shall have vested immediately upon the Company’s receipt of payment of the Purchase Price for such Assigned Interests pursuant to Section 2.03(b), subject to the termination provisions of Section 6.01.   SECTION 2.02.  Payments by the Company.   (a) Monthly Payments in Respect of the Assigned Interests.  In connection with the assignment of the Assigned Interests, Purchaser shall be entitled to receive, in respect of each Payment Month during the Assigned Interest Period: (i) the Pipeline Product Applicable Percentage of Pipeline Product Net Sales (if any) received during such Payment Month; and (ii) the Valves Product Applicable Percentage of Valves Product Net Sales (if any) received during such Payment Month.   (b) Payments to Purchaser.  Within thirty (30) days following the end of each Payment Month during the Assigned Interest Period, the Company shall disburse to the Purchaser Account an amount equal to the amount to which Purchaser is entitled pursuant to Section 2.02(a) of this Agreement (if any) for such Payment Month.  SECTION 2.03.  Closing; Payment of Purchase Price; Deliveries.   (a) Closing.  The closing of the purchase of the Assigned Interests pursuant to this Agreement (the “Closing”) occurred as of the Closing Date. (b) Payment of Purchase Price.  At the Closing, Purchaser paid to the Company the Purchase Price by wire transfer of immediately available funds to such account as designated by the Company prior to the Closing Date. (c) Closing Deliveries.  At the Closing, as a condition precedent to the effectiveness of the Prior Agreement: (i) the Company delivered to Purchaser a duly executed counterpart to this Agreement; and 

 

10  US-DOCS\85889051.6 (ii) Purchaser delivered to the Company (1) payment of the Purchase Price consistent with Section 2.03(b) and (2) a duly executed counterpart to this Agreement. (d) Effectiveness Date Deliveries.  As of the Effective Date, as a condition precedent to the effectiveness of this Agreement: (i) the Company delivered to Purchaser (1) a duly executed counterpart to this Agreement and (2) the MidCap Payoff Letter duly executed by the Company and MidCap;  (ii) Purchaser delivered to the Company a duly executed counterpart to this Agreement;  (iii) Purchaser and Aziyo shall have entered into the Aziyo Royalty Agreement; and (iv) the transactions contemplated by the Asset Purchase Agreement shall have been closed. SECTION 2.04.  No Assumed Obligations; Acquisition of Assigned Interests Alone.  (a) Notwithstanding any provision in this Agreement or any other writing to the contrary, Purchaser acquired only the Assigned Interests and has not assumed any liability or obligation of the Company or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether under this Agreement or otherwise. All such liabilities and obligations shall be retained by and remain obligations and liabilities of the Company or its Affiliates (the “Excluded Liabilities and Obligations”).   (b) Purchaser has acquired no rights other than those expressly assigned herein.  Notwithstanding any provision in this Agreement or any other writing to the contrary, Purchaser has not acquired any rights whatsoever under any Intellectual Property of the Company.  ARTICLE III  Representations and Warranties of the Company SECTION 3.01.  Organization.  As of the Effective Date, each of the Company and its Subsidiaries is a corporation duly incorporated, validly existing and in good standing under the laws of its respective jurisdiction of formation and has all corporate powers and all licenses, authorizations, consents and approvals required to carry on its respective business as now conducted and as proposed to be conducted in connection with this Agreement. SECTION 3.02.  Authorization.  The Company has all necessary power and authority to enter into, execute and deliver this Agreement and to perform all of the obligations to be performed by it hereunder and to consummate the transactions 

 

11  US-DOCS\85889051.6 contemplated hereunder. The Agreement has been duly authorized, executed and delivered by the Company and constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or general equitable principles. SECTION 3.03.  Governmental Authorization.  The execution and delivery by the Company of the Agreement, and the performance by the Company of its obligations hereunder, does not require any notice to, action or consent by, or in respect of, or filing with, any Governmental Authority.  SECTION 3.04.  Ownership.  (a) As of the Effective Date, the Company owns or holds a valid license under all of the Intellectual Property and the Regulatory Approvals which it currently purports to own related to any of the Products free and clear of all liens (except any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable).  As of the Effective Date, neither the Company nor any of its Subsidiaries has granted, nor does there exist, any lien on the Assigned Interests (except any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable). (b) The Company and its Subsidiaries, immediately prior to the purchase by Purchaser of the Assigned Interests, owned, and were the sole holders of, all the Revenue Interests and owned, and were the sole holders of, and/or have and held a valid, enforceable and subsisting license to, all of those other assets that are required to produce any of the Products free and clear of any and all liens (other than any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable).  The Company and its Subsidiaries have not transferred, sold, or otherwise disposed of, or agreed to transfer, sell, or otherwise dispose of any portion of the Revenue Interests other than as contemplated by this Agreement.  By the delivery to Purchaser of the executed Prior Agreement, the Company transferred, conveyed and assigned to Purchaser all of the Company’s rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to Purchaser pursuant to this Agreement, free and clear of any liens (other than any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable).   (c) There is no filed and served or, to the Knowledge of the Company, threatened action, suit, proceeding, investigation or claim by any Person to which the Company is a party that claims that the Intellectual Property or the manufacture, use, marketing, sale, offer for sale, importation or distribution of any Product infringes on any intellectual property of any other Person or constitutes misappropriation of any other Person’s trade secrets or other intellectual property. The Company has not received any written communication containing an offer to license to the Company, or a request that the Company consider whether it wishes to obtain a license, under any intellectual property owned by a third party, in each case, to make, use or sell a Product.  To the Knowledge of the Company, there are no pending unlicensed patent applications owned by any other 

 

12  US-DOCS\85889051.6 Person that, if a patent were to issue thereon without modification or amendment, would limit or prohibit, in any material respect, the manufacture, use or sale of any Product. SECTION 3.05.  Litigation.  As of the date hereof, there is no (a) action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries or (b) any governmental inquiry pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries, in each case with respect to clauses (a) and (b) above, which, if adversely determined, would question the validity of, or could reasonably be expected to have a material adverse effect on the transactions contemplated by this Agreement or could reasonably be expected to have a Material Adverse Effect.  As of the date hereof, there is no action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the Company, threatened against the Company, its Subsidiaries or any other Person relating to any of the Products, the Intellectual Property related to any of the Products, the Regulatory Approvals, the Revenue Interests or the Assigned Interests. SECTION 3.06.  Compliance with Laws.  To the Knowledge of the Company, neither the Company nor any of its Subsidiaries (a) is in violation of, has violated or is under investigation with respect to, and (b) has been threatened to be charged with or been given notice of any violation of, any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license entered by any Governmental Authority applicable to the Company, the Assigned Interests or the Revenue Interests which would reasonably be expected to have a Material Adverse Effect. SECTION 3.07.  Conflicts.  Neither the execution and delivery of this Agreement nor the performance or consummation of the transactions contemplated hereby will: (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provision of (i) any law, rule, ordinance or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which the Company or its Subsidiaries or any of their respective assets or properties are subject or bound or (ii) any contract, agreement, commitment or instrument to which the Company or its Subsidiaries is a party or by which the Company or its Subsidiaries or any of their respective assets or properties is bound or committed; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the articles or certificate of incorporation or bylaws (or other organizational or constitutional documents) of the Company; (c) require any notification to, filing with, or consent of, any Person or Governmental Authority, except such consents that are obtained at or prior to Closing; or (d) give rise to any right of termination, cancellation or acceleration of any right or obligation of the Company, its Subsidiaries or any other Person or to a loss of any right to receive the Revenue Interests or the Assigned Interests, except, in the case of the foregoing clauses (a), (c) or (d), for any such breaches, defaults or other occurrences that would not, individually or in the aggregate, have a Material Adverse Effect. 

 

13  US-DOCS\85889051.6 SECTION 3.08.  Current Indebtedness.  Other than as set forth on Schedule 3.08, there is no indebtedness (other than trade indebtedness in the ordinary course of business) for borrowed money of the Company. SECTION 3.09.  Solvency.  As of the Effective Date, the fair salable value of the Company’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities.  After giving effect to the transactions described in this Agreement, the Company (a) is not left with unreasonably small capital in relation to its business as presently conducted and (b) is able to pay its debts (including trade debts) as they mature. SECTION 3.10.  Financial Statements.  All financial statements for the Company delivered to Purchaser fairly present, in conformity with generally accepted accounting principles, in all material respects, the consolidated financial condition and consolidated results of operations of the Company. SECTION 3.11.  Products.  As of the Effective Date, the only products that are in development by the Company or any of its Affiliates are Pipeline Products and Valve Products. ARTICLE IV  Representations and Warranties of Purchaser SECTION 4.01.  Organization.  Purchaser is a corporation duly incorporated and validly existing under the laws of the State of Delaware.    SECTION 4.02.  Authorization.  Purchaser has all necessary power and authority to enter into, execute and deliver this Agreement and to perform all of the obligations to be performed by it hereunder and to consummate the transactions contemplated hereunder. This Agreement has been duly authorized, executed and delivered by Purchaser and constitutes the valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or general equitable principles. SECTION 4.03.  Conflicts.  Neither the execution and delivery of this Agreement nor the performance or consummation of the transactions contemplated hereby by Purchaser will: (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provision of (i) any law, rule or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which Purchaser or any of its assets or properties may be subject or bound or (ii) any contract, agreement, commitment or instrument to which Purchaser is a party or by which Purchaser or any of its assets or properties is bound or committed; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of Purchaser; or (c) require any notification to, filing with, or consent of, any Person or Governmental 

 

14  US-DOCS\85889051.6 Authority, except, in the case of the foregoing clauses (a) or (c), for any such breaches, defaults or other occurrences that would not, individually or in the aggregate, have a material adverse effect on the ability of Purchaser to perform any of its obligations under this Agreement. ARTICLE V  Covenants SECTION 5.01.  Access; Information. (a) Maintenance of Books and Records.  During the Term, the Company shall keep and maintain, or cause to be kept and maintained, at all times books of account and record consistent with good business practices and customary industry standards adequate to correctly reflect all payments paid and/or payable with respect to the Assigned Interests. (b) Inspection Rights.  Purchaser shall have the right, once a year, to designate a Third Party independent public accounting firm (the “Purchaser Representative”) to visit the Company and its Subsidiaries’ offices and properties where the Company and its Subsidiaries keep and maintain their books and records relating or pertaining to the Revenue Interests and the Assigned Interests for purposes of conducting an audit of such books and records, and to inspect and audit such books and records, during normal business hours, and, upon five (5) Business Days’ written notice given by Purchaser to the Company, the Company will provide such Purchaser Representative reasonable access to such books and records. (c) Audit Costs.  In the event any audit of the books and records of the Company and its Subsidiaries relating to the Revenue Interests and the Assigned Interests by Purchaser and/or any of Purchaser’s representatives reveals that the amounts paid to Purchaser hereunder for the period of such audit have been understated by more than ten percent (10%) of the amounts determined to be due for the period subject to such audit, then the Audit Costs in respect of such audit shall be borne by the Company; and in all other cases, such Audit Costs shall be borne by Purchaser. (d) Monthly Reports.  Commencing with the Payment Month during which the first commercial sale of any of the Products shall occur and continuing during the Term, the Company shall, promptly after the end of each Payment Month of the Company (but in no event later than thirty (30) days following the end of such Payment Month), produce and deliver to Purchaser a Monthly Report for such Payment Month. (e) Periodic Reports.  Commencing with the Fiscal Quarter or Fiscal Year, as applicable, during which the first commercial sale of any of the Products shall occur and continuing during the Term, the Company shall deliver to Purchaser the following financial statements: 

 

15  US-DOCS\85889051.6 (i) Within forty-five (45) days after the end of each Fiscal Quarter, copies of the unaudited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Quarter; and (ii) Within ninety (90) days after the end of each Fiscal Year, copies of the audited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Year. SECTION 5.02.  Confidentiality; Press Release.  (a)  All Confidential Information furnished by the Company to Purchaser or by Purchaser to the Company in connection with this Agreement and the transactions contemplated hereby, as well as the terms, conditions and provisions of this Agreement, shall be kept confidential by Purchaser and the Company. Notwithstanding the foregoing, (i) the Company and Purchaser may disclose such Confidential Information to their partners, directors, employees, managers, officers, investors, bankers, advisors, trustees and representatives, (ii) the Company may disclose the terms, conditions and provisions of this Agreement to any Third Party in connection with (and only in connection with) a transaction with such Third Party that could reasonably be expected to result in (X) a Company Change of Control, (Y) a Product Change of Control or (Z) a sale by the Company of a Subsidiary, division, product line, or other significant portion of its business and (iii) the Company and Purchaser may disclose such Confidential Information as may otherwise be required by applicable law, including filing this Agreement with the SEC; provided, in the case of the foregoing clauses (i) and (ii), that such Persons and such Third Parties shall be informed of the confidential nature of such information and shall be obligated to keep such information confidential pursuant to the terms of this Section 5.02(a); provided, further, that in the case of the foregoing clause (iii), Purchaser shall provide five (5) Business Days’ notice to the Company of any filing with the SEC and consider in good faith a request for confidential treatment of any portion of this Agreement prior to filing with the SEC. (b) Notwithstanding the foregoing clause (a), Purchaser may make a press release or other announcement or public disclosure concerning this Agreement, provided that such press release shall be (x) subject to prior review by the Company and (y) in form and substance reasonably satisfactory to the Company taking into account any commercial sensitivities of the Company. SECTION 5.03.  Efforts; Further Assurance.  Subject to the terms and conditions of this Agreement, each of Purchaser and the Company will use its commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable laws and regulations to consummate the transactions contemplated by this Agreement.  Purchaser and the Company agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement and to vest in Purchaser good, valid and marketable rights and interests in and to the Assigned Interests. Company further agrees to use its commercially reasonable efforts to develop, launch and commercialize the Products.    

 

16  US-DOCS\85889051.6 SECTION 5.04.  Licenses. During the Term, the Company shall maintain each of the licenses made or entered into with respect to the Products that is required in order to be able to market and sell any of the Products in good standing and shall not take any action, or omit to fail to take any action (including making necessary payments), which would result in a breach or early termination of any license agreements or any rights thereunder, except in each case to the extent the same would not affect Purchaser’s rights or license hereunder, and provided that, the Company’s obligations with respect to making necessary payments under such licenses shall be contingent upon Purchaser making corresponding payments to the Company pursuant to this Agreement. The Company covenants that it shall not amend, modify or supplement the terms of, or waive any rights under, any such license (except as those that may be entered into between the Company and Purchaser) without the prior written consent of Purchaser where and to the extent that any amendment or waiver would adversely affect the rights and licenses granted to Purchaser pursuant to this Agreement. The Company shall promptly notify Purchaser upon receipt by the Company of any notice from any in-bound licensor of any actual or alleged breach under any license that could result in the termination of such agreement or a material reduction or other material limitation in the Company’s rights thereunder to the extent the same would adversely affect Purchaser’s rights or license hereunder, and the Company shall promptly cure any such breach within the allotted cure period and if it is unwilling or unable to do so, the Company shall timely notify Purchaser and Purchaser shall have the right to cure such breach on the Company’s behalf.    SECTION 5.05.  Remedies Event.  During the Term, if a Remedies Event shall have occurred, the Company shall not, without the consent of Purchaser, distribute any dividend, retire any indebtedness for borrowed money or engage in any transaction that would result in a Company Change of Control. SECTION 5.06.  Diligence.  During the Assigned Interest Period with respect to the Products, the Company shall use reasonable commercial efforts to develop the Products and obtain Regulatory Approval for at least one (1) Product and, after receiving the applicable Regulatory Approval, to commercialize at least one (1) Product in the United States and in Europe. SECTION 5.07.  Indebtedness; Sale of Revenue Interests.  Except set forth in Schedule 5.07, during the Term, unless Purchaser shall otherwise consent in writing, the Company shall not, other than in connection with any Permitted Transaction, (x) incur, create, assume or permit to exist any indebtedness for borrowed money of the Company other than indebtedness of the Company as of the Closing Date or (y) sell, assign, transfer, encumber, hypothecate, grant a security interest in or convey the Assigned Interests and any proceeds and products thereof, the Assigned Interest Related Collateral and any Revenue Interests other than by the terms of this Agreement. 

 

17  US-DOCS\85889051.6 ARTICLE VI  Termination SECTION 6.01.  Termination.  Except as provided in this Section 6.01 and in Section 6.02, this Agreement shall terminate upon expiration of the Assigned Interest Period with respect to all Products (the “Term”). If any payments are accrued hereunder on or prior to that date and are required to be made by one of the Parties hereunder, this Agreement shall remain in full force and effect until any and all such payments have been made in full.  Upon expiration or termination of this Agreement in accordance with its terms, all right, title, and interest in and to the Assigned Interests shall automatically revert to Company, and Purchaser will have no further rights in or with respect to the Assigned Interests. SECTION 6.02.  Effect of Termination.  In the event of the termination of this Agreement pursuant to Section 6.01, this Agreement shall forthwith become void, impose no liability on the part of any Party hereto or its Affiliates, directors, officers, stockholders, partners, managers or members and have no effect other than the provisions of this Section 6.02, Section 5.02 and Article VII hereof, which shall survive any such termination.  ARTICLE VII  Miscellaneous SECTION 7.01.  Survival.  All representations and warranties made herein or in any other writing delivered pursuant hereto shall survive the execution and delivery of this Agreement and shall continue to survive until the expiration or termination of this Agreement in accordance with Article VI. SECTION 7.02.  Notices.  All notices, consents, waivers and communications hereunder given by any party to the other shall be in writing (including facsimile transmission) and delivered personally, by telegraph, telecopy, telex or facsimile, by a recognized overnight courier, or by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, in each case addressed (with a copy by email): If to Purchaser to:  Ligand Pharmaceuticals Incorporated  3911 Sorrento Valley Boulevard, Suite 110  San Diego, CA 92121  Attention: Matthew Korenberg  Email:  mkorenberg@ligand.com With a copy to:  Latham & Watkins LLP 

 

18  US-DOCS\85889051.6  12670 High Bluff Drive  San Diego, CA 92130  Attention: Scott N. Wolfe  Email:  scott.wolfe@lw.com If to the Company to:  CorMatrix Cardiovascular, Inc.  1100 Old Ellis Road  Roswell, GA 30076  Attention: John C. Thomas, Jr.  Email:  jthomas@cormatrix.com With a copy to:  Ledbetter Wanamaker Glass LLP 1201 Peachtree Street NE, Suite 1501 Atlanta, Georgia  30361  Attention: Larry D. Ledbetter  Email:  lledbetter@lwglaw.com  or to such other address or addresses as Purchaser or the Company may from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt. All such notices, consents, waivers and communications shall: (a) when posted by certified or registered mail, postage prepaid, return receipt requested, be effective three (3) Business Days after dispatch, (b) when telegraphed, telecopied, telexed or facsimiled, be effective upon receipt by the transmitting party of confirmation of complete transmission, or (c) when delivered by a recognized overnight courier or in person, be effective upon receipt when hand delivered. SECTION 7.03.  Successors and Assigns.  (a)  The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.   (b) Upon the consent of Purchaser (which consent may not be unreasonably withheld, delayed or conditioned for any proposed assignment to any reasonably creditworthy potential Acquiror or other proposed assignee), the Company may assign all or any applicable part of its rights and obligations under this Agreement to any Acquiror in respect of any Product Change of Control, subject to the assumption by such Acquiror of the obligations set forth in Section 2.02 or to any other proposed assignee.  For purposes of this Section 7.03(b), any Person the creditworthiness of whom clearly exceeds the creditworthiness of the Company shall be deemed to be reasonably creditworthy.   (c) Solely upon the consent of the Company (which consent may not be unreasonably withheld, delayed or conditioned, other than in respect of any proposed assignment to any direct competitor of the Company, in respect of which such consent may be granted or withheld by the Company in its sole discretion), Purchaser may assign any of its obligations or rights under the Agreement without restriction; provided that, 

 

19  US-DOCS\85889051.6 notwithstanding the foregoing, Purchaser may assign its rights and/or delegate its obligations under this Agreement to an Affiliate, to any Person in a transaction in which Purchaser also assigns all of its right, title and interest in all or substantially all of its assets to the same party contemporaneous with the assignment of this Agreement, or to a successor, whether by way of merger, sale of stock or otherwise, without the Company’s prior written consent.  In advance of any proposed assignment by Purchaser to any proposed assignee, Purchaser shall provide to the Company any information concerning such proposed assignment and such proposed assignee as may be reasonably requested by the Company.   SECTION 7.04.  Indemnification.  (a) The Company hereby indemnifies and holds Purchaser and its Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each, a “Purchaser Indemnified Party”) harmless from and against any and all Losses incurred or suffered by any Purchaser Indemnified Party arising out of any breach of any representation or warranty made by the Company in this Agreement. (b) Purchaser hereby indemnifies and holds the Company, its Affiliates and any of their respective partners, directors, managers, officers, employees and agents (each, a “Company Indemnified Party”) harmless from and against any and all Losses incurred or suffered by a Company Indemnified Party arising out of any breach of any representation or warranty made by Purchaser in this Agreement. (c) If any claim, demand, action or proceeding (including any investigation by any Governmental Authority) shall be brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to the preceding paragraphs, the indemnified party shall, promptly after receipt of notice of the commencement of any such claim, demand, action or proceeding, notify the indemnifying party in writing of the commencement of such claim, demand, action or proceeding, enclosing a copy of all papers served, if any; provided, that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under the foregoing provisions of this Section 7.04 unless, and only to the extent that, such omission results in the forfeiture of, or has a material adverse effect on the exercise or prosecution of, substantive rights or defenses by the indemnifying party.  In case any such action is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section 7.04 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation.  In any such proceeding, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the expense of such indemnified party unless the indemnifying party and the indemnified party shall 

 

20  US-DOCS\85889051.6 have mutually agreed to the retention of such counsel.  It is agreed that the indemnifying party shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such indemnified parties.  The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. (d) Purchaser’s sole remedy shall be to recover any monetary damages associated with a breach of a representation or warranty made by the Company in this Agreement, subject to the other terms and provisions contained in this Agreement.   SECTION 7.05.  No Implied Representations and Warranties.  Each Party acknowledges and agrees that, other than the representations and warranties specifically contained in this Agreement, there are no representations or warranties of either Party or any other Person either expressed or implied with respect to the Assigned Interests or the transactions contemplated hereby. Without limiting the foregoing, Purchaser acknowledges and agrees that (a) Purchaser and its Affiliates, together with its and its Affiliates’ representatives, have made their own investigation of the Products, the Intellectual Property related to the Products and the Regulatory Approvals and are not relying on any implied warranties or upon any representation or warranty whatsoever as to the future amount or potential amount of the Assigned Interests or as to the creditworthiness of Company and (b) except as expressly set forth in any representation or warranty in the Agreement, Purchaser shall have no claim or right to indemnification pursuant to Section 7.04 (or otherwise) with respect to any information, documents or materials furnished to Purchaser, any of its Affiliates, or any of its or its Affiliates’ representatives, including any information, documents or material made available to Purchaser, its Affiliates or any of its and its Affiliates’ representatives in any data room, presentation, management presentation, interview or any other form relating to the transactions contemplated hereby. SECTION 7.06.  Independent Nature of Relationship.  (a)  The relationship between the Company and Purchaser is solely that of seller and purchaser, and neither Purchaser nor the Company has any fiduciary or other special relationship with the other or any of their respective Affiliates.  Nothing contained herein shall be deemed to constitute the Company and Purchaser as a partnership, an association, a joint venture or other kind of entity or legal form for any purposes, including any tax purposes. (b) No officer or employee or agent of Purchaser will be located at the premises of the Company or any of its Affiliates, except in connection with an audit 

 

21  US-DOCS\85889051.6 performed pursuant to Section 5.01. No officer, manager or employee of Purchaser shall engage in any commercial activity with the Company or any of its Affiliates other than as contemplated herein or as otherwise separately agreed in writing. (c) Purchaser and/or any of its Affiliates shall not at any time obligate the Company, or impose on the Company any obligation, in any manner or respect to any Person not a party hereto.  The Company and/or any of its Affiliates shall not at any time obligate Purchaser, or impose on Purchaser any obligation, in any manner or respect to any Person not a party hereto. SECTION 7.07.  Entire Agreement.  This Agreement, together with the Exhibits and Schedules hereto (which are incorporated herein by reference), constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements (including any term sheet), understandings and negotiations, both written and oral, between the Parties with respect to the subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein has been made or relied upon by either Party hereto. None of this Agreement, nor any provision hereof, is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder or in respect hereof. SECTION 7.08.  Amendments; No Waivers.  (a) Neither this Agreement nor any term or provision hereof may be amended, changed or modified except with the written consent of all parties hereto.  No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the party against whom such waiver is sought to be enforced. (b) No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.  The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. SECTION 7.09.  Interpretation.  When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference shall be to an Article, Section, Schedule or Exhibit to this Agreement unless otherwise indicated.  The words “include”, “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation”.  Neither party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other. SECTION 7.10.  Headings and Captions.  The headings and captions in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. SECTION 7.11.  Counterparts; Effectiveness.  This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which 

 

22  US-DOCS\85889051.6 together shall constitute one and the same instrument.  This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto.  Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original. SECTION 7.12.  Severability.  If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect. SECTION 7.13.  Expenses.  Each of Purchaser and the Company will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by this Agreement. SECTION 7.14.  Governing Law; Jurisdiction.  (a) This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof. (b) Any legal action or proceeding with respect to this Agreement may be brought in any state or federal court of competent jurisdiction in the State of New York, County of New York.  By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in respect of its property, generally and unconditionally the exclusive jurisdiction of such courts.  Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens, which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of this Agreement. (c) Each party hereto hereby irrevocably consents to the service of process out of any of the courts referred to in clause (b) of this Section 7.14 in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement.  Each party hereto hereby irrevocably waives any objection to such service of process and further irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder that service of process was in any way invalid or ineffective.  Nothing herein shall affect the right of a party to serve process on the other party in any other manner permitted by law. ARTICLE VIII  Intercreditor Matters SECTION 8.01.  Purchase and Sale Treatment; Recharacterization.  (a) It is the intention of the Parties to this Agreement that the conveyance by the Company to Purchaser of the Assigned Interests pursuant to this Agreement shall constitute a purchase and sale, and such purchase and sale of the Assigned Interests hereunder shall be treated as a sale for all purposes, other than federal and state income tax purposes.  The provisions of this Agreement shall be construed to further these intentions of the Parties. 

 

23  US-DOCS\85889051.6 (b) The Assigned Interests and any amounts received by the Company in respect of the Assigned Interests (subject to any adjustments for Excluded Costs) are not, and are not intended to be, the property of the Company (or, in the event of a Bankruptcy Event, any estate created thereby by operation of applicable law or otherwise) but is possessed by the Company in trust solely on behalf of Purchaser pending disbursement to Purchaser or as otherwise provided for in Section 5.09(b), in each case, as contemplated hereby. (c) If, notwithstanding clause (b), the conveyance of the Assigned Interests is subject to a Recharacterization, the Parties intend that the Company shall be deemed hereunder to have granted, and the Company does hereby grant, to Purchaser a first priority security interest in favor of Purchaser, to secure the obligations to make the payments under Section 2.02 in the Assigned Interests and all proceeds and products thereof. (d) If, notwithstanding clause (b), the conveyance of the Assigned Interests is subject to a Recharacterization, the Parties intend that the Company shall be deemed hereunder to have granted, and the Company does hereby grant a first priority security interest in favor of Purchaser, to secure the obligations to make payments under Section 2.02  in the Assigned Interest Related Collateral.  SECTION 8.02.  Priority.  The security interest granted in Section 8.01(c) shall be for all purposes senior in right to any other lien. SECTION 8.03.  Control Agreements.  (a)  The Purchaser agrees to terminate on or before ten (10) Business Days after the Effective Date (i) that certain Agreement Regarding Pledged Collateral, dated June 8, 2016, among the Purchaser, the Company and State Bank and Trust and (ii) if requested by the Company, any other control or similar agreements identified by the Company that Purchaser and the Company may have entered into with any bank or financial institution in order to cause such bank or financial institution to comply at any time with instructions from Purchaser to such bank or financial institution directing the disposition of funds in any deposit account of the Company held with such bank or financial institution.   (b) At least ten (10) Business Days prior to the first commercial sale of any Product, the Company shall notify Purchaser of such first commercial sale and shall (i) establish a separate bank account (the “Special Account”), (ii) grant Purchaser a first priority security lien in the Special Account, (iii) enter into a depositary account control agreement naming Purchaser as a lien holder, and (iv) transfer the Assigned Interests to the Special Account on a weekly basis. SECTION 8.04.  Termination or Release.  (a) Upon termination of this Agreement in accordance with its terms and payment in full of all Obligations (other than any contingent indemnification obligations with respect to which no claim has been made) owing by the Company to Purchaser, all right, title, and interest in and to the Assigned Interest Related Collateral shall automatically revert to Company and Purchaser will have 

 

24  US-DOCS\85889051.6 no further rights in or with respect to the Assigned Interest Related Collateral and all security interests granted pursuant to this Article VIII shall terminate and be released.   (b) At the Company’s request, Purchaser shall subordinate its liens with respect to any of the Assigned Interest Related Collateral or terminate and release its liens with respect to any of the Assigned Interest Related Collateral subject to any Permitted Transaction. (c) In connection with any termination or release pursuant to this Section 8.04, Purchaser shall execute and deliver to the Company all documents that the Company shall reasonably request to evidence such termination or release.  SECTION 8.05.  Financing Statements.  The Company hereby irrevocably authorizes the Purchaser at any time and from time to time to file in any filing office and/or recording or registration office in any relevant jurisdiction any financing statements  and amendments thereto that contain the information required by Article 9 of the UCC of each applicable jurisdiction for the filing of any financing statement or amendment relating to the collateral in which the Purchaser was granted a security interest pursuant to the terms of this Agreement.  Purchaser shall provide reasonable notice to the Company of all such financing statement filings made by Purchaser on or about the date hereof, and any subsequent filings or amendments, supplements or terminations of existing filings, made by the Company from time to time thereafter.  ARTICLE IX  Remedies SECTION 9.01.  Remedies.  If any Remedies Event shall occur and be continuing, Purchaser may exercise all rights and remedies of a secured party under the UCC or under any other applicable law and in equity.  [Remainder of this page intentionally left blank]rmti_Ex10_68

		

			Exhibit 10.68

		

		
			[* *] Portions of this exhibit have been omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 
		

		
			FIRST AMENDMENT TO 
		

		
			EXCLUSIVE DISTRIBUTION AGREEMENT
		

		
			This First Amendment to the Exclusive Distribution Agreement (this “First Amendment”) is executed this 23rd day of June, 2017, by and between Rockwell Medical, Inc., a Michigan corporation (the “Company”) and Baxter Healthcare Corporation, a Delaware corporation (“Distributor”).  
		

		
			RECITALS
		

			
	
			
				 A.
			Distributor and the Company are parties to that certain Exclusive Distribution Agreement, effective as of October 2, 2014 (the “Agreement”).

			
	
			
				 B.
			Distributor and the Company are parties to an arbitration to settle certain disputes arising out of the Agreement and desire to enter into this First Amendment in connection with a settlement of their disputes.

		
			AGREEMENT
		

		
			In consideration of the foregoing and mutual covenants and agreements contained in this First Amendment and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:
		

			
	
			
				 1.
			Section 1.1 of the Agreement is amended by adding paragraph (f) as follows:

		
			(f)Notwithstanding anything in this Agreement to the contrary, it shall not be a breach of the Agreement if the Company discusses, negotiates or enters into an amendment or other modification to the Designated Customer’s Original Customer Contract that increases the prices paid by the Designated Customer to the Company thereunder; provided that such amendment or other modification shall not otherwise modify such contract without Distributor’s prior written consent, which consent shall not be unreasonably withheld.  
		

			
	
			
				 2.
			Section 1.3 of the Agreement is amended and restated in its entirety as follows:

		
			Original Customer Contracts.  As and when requested by the Distributor, the Company shall assign to the Distributor (to the extent assignable without further Third Party consent) the Company’s rights under the Original Customer Contracts to Commercialize the Products in the Territory during the Term.  The Distributor shall assume the Company’s obligations under each assigned Original Customer Contract, but only to the extent that such obligations are required to be performed after the effective date of the assignment.  With respect to the Designated Customer’s Original Customer Contract, until (a) the Company has assigned such Original Customer Contract to Distributor with the Designated Customer’s consent,  or (b) Distributor enters into a replacement contract for Concentrate Products with the Designated Customer (or its Affiliate), the Company shall retain all Economic Losses arising from such Original Customer Contract and the Company shall pay to the Distributor the amount equivalent to the Economic Gains from such Original Customer Contract.  “Economic Losses” for this purpose shall be the amount by which (i) the fees and costs 

		 

		

			1

		

		

			4816-3189-0251.2101129\000001

		

 

relating to Support Services rendered under Exhibit C with respect to Products shipped to the Designated Customer under the Original Customer Contract using the allocation method set forth in Exhibit C exceed (ii) (A) the aggregate price paid for Products by the Designated Customer minus (B) the Contract Price for Products ordered by the Designated Customer.  “Economic Gains” for this purpose shall be the amount by which the aggregate price paid for Products by the Designated Customer exceeds the aggregate of (i) the Contract Price for Products ordered by the Designated Customer and (ii) the fees and costs relating to Support Services rendered under Exhibit C with respect to the Products shipped to the Designated Customer under the Original Customer Contract using the allocation method set forth in Exhibit C .  For the avoidance of doubt, this Section 1.3 shall impose on the Distributor no obligation to make any payment to the Company relative to the Designated Customer’s Original Customer Contract.  Distributor shall use reasonable commercial efforts to negotiate a  new contract with a  price increase directly with the Designated Customer (or its Affiliate) to replace the Designated Customer’s Original Customer Contract.
		

			
	
			
				 3.
			Section 3.8 of the Agreement is amended and restated in its entirety as follows:

		
			(a)(1) Subject to the terms of this Section 3.8, the exclusive Distributor Rights granted to the Distributor under Section 1.1, other than with respect to the Designated Customer, shall become non‐exclusive at the option of the Company if the quantity of Concentrate Products, measured in gallons, ordered by the Distributor (or directly by its customers) in the United States during any Calendar Year is less than the relevant minimum order threshold for such Calendar Year determined as follows (each, a “Minimum Order Threshold”):
		

			
					
						 

					
					
						 

				
	
					
						Calendar Year

					
					
						Minimum Order Threshold

				
	
					
						2017

					
					
						[* *]

				
	
					
						2018 

					
					
						[* *]

				
	
					
						2019

					
					
						[* *]

				
	
					
						2020

					
					
						[* *]

				
	
					
						2021 

					
					
						[* *]

				
	
					
						2022

					
					
						[* *]

				
	
					
						2023

					
					
						[* *]

				
	
					
						2024

					
					
						[* *]

				
	
					
						 

					
					
						 

				
	
					
						2025 and each Calendar Year thereafter during the Term

					
					
						[* *]% of the Baseline Amount for Calendar Year 2025, and an incremental [* *]% increase for each Calendar Year thereafter during the Term (resulting in a Minimum Order Threshold of [* *]% of the Baseline Amount for final Calendar Year).

				

		
			For purposes of determining whether the Minimum Order Threshold has been achieved for any Calendar Year, except as provided in clause (a)(3) of this Section 3.8, gallons ordered by or on behalf of the Designated Customer, or by Distributor, its Affiliates, Marketing Partners, sub-distributors or otherwise for resale or distribution, directly or indirectly, to Designated Customer or its Affiliates shall not at any time be counted as gallons ordered.  
		

		
			

		 

		

			2

		

 

		

		
			(2)Subject to the terms of this Section 3.8, the exclusive Distributor Rights granted to the Distributor under Section 1.1 with respect to the Designated Customer shall become non-exclusive at the option of the Company if, after (A) the Company obtains consent from the Designated Customer and the Designated Customer’s Original Customer Contract has been assigned to Distributor,  or (B) Distributor enters into a new contract for Concentrate Products with the Designated Customer (or its Affiliate if such Affiliate has executed such new contract instead of the Designated Customer), the quantity of Concentrate Products, measured in gallons, ordered by (i) Designated Customer (or its Affiliate if such Affiliate has executed such new contract) or (ii) the Distributor, its Affiliates, Marketing Partners, sub-distributors or otherwise for resale or distribution, directly or indirectly, to Designated Customer or its Affiliates during any Calendar Year following the Designated Customer Baseline Year is less than the relevant minimum order threshold for such Calendar Year (each, a “Designated Customer Minimum Order Threshold”).  The Designated Customer Minimum Order Threshold shall be [* *]% of the Designated Customer Baseline Amount in the first Calendar Year after the Designated Customer Baseline Year, and shall increase [* *]% per year thereafter ([* *]%, [* *]% etc.) through 2024, and thereafter shall increase in a similar manner by [* *]% each Calendar Year until the end of the Term of the Agreement.  For purposes of determining whether the Designated Customer Minimum Order Threshold has been achieved for any Calendar Year,  except as provided in clause (a)(3) of this Section 3.8, gallons ordered other than by or on behalf of the Designated Customer, or by Distributor, its Affiliates, Marketing Partners, sub-distributors or otherwise for resale or distribution, directly or indirectly, to Designated Customer or its Affiliates shall not at any time be counted as gallons ordered.  
		

		
			(3)For purposes of this Section 3.8 and the related definitions, Concentrate Products in powder form shall be measured in gallons by applying the conversion ratios set forth in Exhibit E hereto.  The Company represents and warrants that such conversion ratios are consistent with (i) the mixing instructions provided by the Company to its customers as of the Effective Date, and (ii) any mixing information set forth in the Regulatory Approvals for such Concentrate Products.  
		

		
			To the extent that the gallons of Concentrate Products ordered for any Calendar Year exceed the Minimum Order Threshold or Designated Customer Minimum Order Threshold for such Calendar Year, the excess may be applied against the other Threshold for the same Calendar Year or may be carried forward and applied against the Minimum Order Threshold or Designated Customer Minimum Order Threshold, at Distributor’s option, without duplication, for future Calendar Years until the entire excess has been fully-credited.  Solely for illustration purposes, if the Minimum Order Threshold for Calendar Year 2  is [* *] and the gallons of Concentrate Product ordered in Calendar Year 2 other than by or on behalf of the Designated Customer, or by Distributor, its Affiliates, Marketing Partners, sub-distributors or otherwise for resale or distribution, directly or indirectly, to Designated Customer or its Affiliates are [* *], then a total of [* *] gallons may be applied, at the Distributor’s option, against the Designated Customer Minimum Order Threshold for Calendar Year 2 or against the Minimum Order Threshold or Designated Customer Minimum Order 

		 

		

			3

		

 

Threshold for Calendar Year 3 and future years until the [* *] gallons has been fully-credited.  
		

		
			(b)Notwithstanding any other provision hereof, if the Distributor’s Commercialization of any Concentrate Product (or Concentrate Products) in any Calendar Year is materially and adversely impacted by a Disruptive Event for a period of at least [* *] days during such Calendar Year, then (i) the Distributor shall have no obligation to achieve the Minimum Order Threshold or Designated Customer Minimum Order Threshold, whichever is applicable, for such Calendar Year, and (ii) the Minimum Order Threshold or Designated Customer Minimum Order Threshold, whichever is applicable, for the following Calendar Year shall be the Minimum Order Threshold or Designated Customer Minimum Order Threshold, whichever is applicable, in effect during the Calendar Year in which the Disruptive Event occurred and the schedule of Minimum Order Thresholds or Designated Customer Minimum Order Thresholds, whichever is applicable, for future Calendar Years shall be adjusted accordingly.  The Distributor shall notify the Company in writing as soon as possible if it discovers facts or circumstances that are reasonably likely to materially and adversely impact its Commercialization of a Concentrate Product (or Concentrate Products) for purposes of this Section 3.8(b).  
		

		
			(c)(1)If the Distributor fails to achieve the Minimum Order Threshold for any Calendar Year and if the Company believes that the Distributor has not been excused from achieving the Minimum Order Threshold by reason of any Disruptive Event as set forth in Section 3.8(b), then the Company shall notify the Distributor in writing within [* *] days after the end of such Calendar Year.  Upon receipt of such notice, the Distributor shall have a period of [* *] days (the “Shortfall Cure Period”) to submit one or more Firm Orders to make up for any shortfall and, upon so doing, the gallons of Concentrate Product reflected in such Firm Orders shall count (without duplication) toward the Distributor’s satisfaction of the Minimum Order Threshold for such Calendar Year.  
		

		
			(2)If the Distributor fails to achieve the Designated Customer Minimum Order Threshold for any Calendar Year and if the Company believes that the Distributor has not been excused from achieving the Minimum Order Threshold by reason of any Disruptive Event as set forth in Section 3.8(b), then the Company shall notify the Distributor in writing within [* *] days after the end of such Calendar Year.  Upon receipt of such notice, the Distributor shall have the Shortfall Cure Period to submit one or more Firm Orders to make up for any shortfall and, upon so doing, the gallons of Concentrate Product reflected in such Firm Orders shall count (without duplication) toward the Distributor’s satisfaction of the Designated Customer Minimum Order Threshold for such Calendar Year.  
		

		
			(3)If the Company assigns the Designated Customer’s Original Customer Contract to Distributor, or Distributor enters into a new contract for Concentrate Products with the Designated Customer (or its Affiliate if such Affiliate has executed such new contract instead of the Designated Customer), and, in either case, such contract is terminated before a Designated Customer Baseline Amount is established and the termination is not caused by, or attributable to any action taken or the failure to take any 

		 

		

			4

		

 

action, by the Company, and the termination is caused by the Distributor’s breach of its agreement with the Designated Customer, then the Company’s sole remedy shall be is to render non-exclusive the Distributor Rights as to the Designated Customer.  In order to exercise its right to render such Distributor Rights non-exclusive, the Company must notify the Distributor in writing thereof within [* *] days after it has been made aware of such termination.  If the Company fails to so notify the Distributor within such [* *]-day period, such Distributor Rights shall remain exclusive.  If the Company so notifies the Distributor within such [* *]-day period, then the Distributor Rights shall be non-exclusive as to the Designated Customer effective as of the date the Distributor receives such notice from the Company; provided, however, that if the Distributor contends that the condition set forth in this Section 3.8(c)(3) has not been satisfied, then the Distributor Rights shall remain exclusive until the dispute is resolved in accordance with Section 11.15.
		

		
			(d)(1)The Company’s sole remedy for the Distributor’s failure to achieve the Minimum Order Threshold under Section 3.8(a)(1) is to render non-exclusive the Distributor Rights as to all customers other than the Designated Customer.  In order to exercise its right to render the Distributor Rights as to all customers other than the Designated Customer non-exclusive, the Company must notify the Distributor in writing thereof within [* *] days after the expiration of the Shortfall Cure Period.  If the Company fails to so notify the Distributor within such [* *]-day period, the Distributor Rights as to all customers other than the Designated Customer shall remain exclusive.  If the Company so notifies the Distributor within such [* *]-day period, then the Distributor Rights as to all customers other than the Designated Customer shall be non-exclusive effective as of the date the Distributor receives such notice from the Company; provided, however, that if the Distributor contends that the applicable Minimum Order Threshold has been satisfied or that such Minimum Order Threshold does not apply by reason of a Disruptive Event, then the Distributor Rights as to all customers other than the Designated Customer shall remain exclusive until the dispute is resolved in accordance with Section 11.15.
		

		
			(2)The Company’s sole remedy for the Distributor’s failure to achieve the Designated Customer Minimum Order Threshold is to render non-exclusive the Distributor Rights as to the Designated Customer.  In order to exercise its right to render such Distributor Rights non-exclusive, the Company must notify the Distributor in writing thereof within [* *] days after the expiration of the Shortfall Cure Period.  If the Company fails to so notify the Distributor within such [* *]-day period, such Distributor Rights shall remain exclusive.  If the Company so notifies the Distributor within such [* *]-day period, then the Distributor Rights shall be non-exclusive as to the Designated Customer effective as of the date the Distributor receives such notice from the Company; provided, however, that if the Distributor contends that the applicable Designated Customer Minimum Order Threshold has been satisfied or that such Designated Customer Minimum Order Threshold does not apply by reason of a Disruptive Event, then the Distributor Rights shall remain exclusive until the dispute is resolved in accordance with Section 11.15.
		

		
			

		 

		

			5

		

 

		

			
	
			
				 4.
			The introductory language at the beginning of Section 4.5 of the Agreement is amended and restated in its entirety as follows 

		
			West Coast Facility Fee. The following shall apply if the Company and the Distributor have determined to establish a West Coast Facility, such determination is set forth in writing and signed by the Parties and the Company has complied with Section 3.9:  
		

			
	
			
				 5.
			Section 4.6 of the Agreement is amended by adding a new paragraph (d) as follows:

		
			(d)In the event Distributor believes in good faith Rockwell has breached Section 1.1 and such breach does not entitle Distributor to terminate the Agreement under Section 10.2(b) or Distributor otherwise chooses not to pursue termination as a remedy, Distributor may give written notice of such alleged breach to the Company under this Section 4.6(d).  If the Company disputes such alleged breach, it shall notify Distributor of such dispute within ten Business Days after receipt of such notice, in which case such dispute shall be resolved in accordance with Section 11.15.  If the Company does not dispute such alleged breach or if upon resolution of a dispute in accordance with Section 11.15, it is determined that such breach exists, then Rockwell shall have [* *] days after receipt of such notice or determination of breach, as applicable, in which to remedy such default.  If such default is not remedied in the time period set forth above, Distributor shall have the right to receive liquidated damages in the amount of $[* *] and Distributor reserves the right to take the position that certain breaches (such as a breach of exclusivity) cannot be cured.
		

			
	
			
				 6.
			Section 9.3 of the Agreement is amended and restated in its entirety as follows:

		
			Obligations.  The recipient of Confidential Information shall (a) use such Confidential Information solely and exclusively in connection with the exercise of its rights and the discharge of its obligations under this Agreement and (b) not disclose such Confidential Information without the prior written consent of the disclosing Party to any Person other than (x) those of its agents and representatives who need to know such Confidential Information for such permitted use and who are bound by obligations of confidentiality with respect thereto and (y) potential financing sources, underwriters, placement agents and potential advisors, in each case who are bound by obligations of confidentiality with respect thereto.  Notwithstanding the foregoing, the recipient of Confidential Information may disclose it to the extent necessary to comply with Applicable Laws or with an Order issued by a court or regulatory body with competent jurisdiction; provided that, in connection with such disclosure, the recipient shall (i) provide reasonable advance notice of such disclosure to the disclosing Party; (ii) limit the disclosure to the information that is legally required to be disclosed, and (iii) use commercially reasonable efforts to obtain confidential treatment or an appropriate protective order, to the extent available, with respect to such Confidential Information.  The obligations under this Section 9.3 shall remain in effect from the Effective Date through the fifth anniversary of the termination or expiration of this Agreement.
		

		
			

		 

		

			6

		

 

		

			
	
			
				 7.
			The second bullet in Section 10.3 of the Agreement is amended and restated in its entirety as follows:

		
			     Articles 7, 8, 9, 10 and 11 (excluding Section 11.17); and
		

			
	
			
				 8.
			Section 11.15 of the Agreement is amended and restated in its entirety as follows:

		
			(a)Any and all disputes, claims or controversies (“disputes”) arising out of or relating to this Agreement, including without limitation, any dispute as to the existence, validity, performance, breach or termination of this Agreement, shall be resolved in the following manner.  A party must first send written notice of the dispute to the other party for attempted resolution by negotiation between executives who have authority to settle the controversy. Negotiations must be conducted within 14 days after such notice is received (all references to “days” in this provision are to calendar days).  If the parties fail to meet or if the matter has not been resolved within 14 days, the parties shall mediate their dispute within 30 days after the 14 day period has expired.  If the mediation fails to resolve all disputes or if the mediation has not been scheduled within 30 days, either party may initiate arbitration with respect to the matters submitted to negotiation and mediation by filing a written demand for arbitration.  Disputes shall be settled by final and binding arbitration administered by the International Institute for Conflict Prevention & Resolution (CPR) in accordance with its rules. The place of arbitration shall be Chicago, IL.  Notwithstanding the foregoing, to the extent a party is seeking injunctive relief either party may immediately bring a proceeding seeking preliminary injunctive relief or a temporary restraining order in a court having jurisdiction, and this relief shall remain in effect until the parties reach a resolution or so long as the arbitrator(s) feel as appropriate.
		

		
			(b)For disputes under $[* *], one arbitrator shall either be mutually agreed by the parties or appointed in accordance with the arbitrator’s rules. For disputes over $[* *], a panel of three arbitrators shall be appointed in accordance with the arbitrator’s rules.  Within 30 days following the initiation of an arbitration proceeding, the arbitrator(s) will be selected.  No later than 60 days after selection, the arbitrator(s) shall hold a hearing to resolve each of the issues identified by the parties.  All arbitration proceedings shall be conducted in the English language.  At least 7 days prior to the hearing, each party shall submit the following to the other party and the arbitrator(s):
		

		
			     A copy of all exhibits on which such party intends to rely in any oral or written presentation to the arbitrator(s);
		

		
			     A list of any witnesses such party intends to call at the hearing, and a short summary of the anticipated testimony of each witness;
		

		
			     A proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue.  The proposed rulings and remedies shall not contain any recitation of the facts or of any legal arguments. The parties agree that neither side shall seek as part of its remedy any punitive damages; and
		

		
			     A brief in support of such party’s proposed rulings and remedies, provided the brief shall not exceed 20 pages.
		

		
			

		 

		

			7

		

 

		

		
			(c)Within 14 days following completion of the hearing, each party may submit to the other party and the arbitrator(s) a post-hearing brief in support of its proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed 10 pages.  The arbitrator(s) shall rule on each disputed issue within 21 days following completion of the hearing.  Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the parties on each disputed issue and may adopt one party’s proposed rulings and remedies on some issues and the other parties proposed rulings and remedies on other issues.  The arbitrator(s) shall not adopt any written opinion or otherwise explain the basis of the ruling.  If the arbitrator(s) rule in favor of one party on all disputed issues, the losing party shall pay the prevailing party’s fees and expenses (including attorneys’ fees).  If the arbitrator(s) rule in favor of one party on some issues and the other party on other issues, the arbitrator(s) shall allocate fees and expenses in a way that bears a reasonable relationship to the ruling.  The rulings of the arbitrator(s) and the allocation of fees and expenses shall be binding, non-reviewable and non-appealable, and may be entered as a final judgment in any court having jurisdiction.  Except as required by law, the parties agree to keep confidential the existence of the arbitration, the submissions made by the parties (including exhibits, testimony, proposed rulings and briefs) and the decisions made by the arbitrator(s), including its awards. 
		

			
	
			
				 9.
			Exhibit A of the Agreement is amended by deleting the definition of “Excluded Claim,” amending and restating the definition of Baseline Amount and adding the definitions of “Calendar Year,” “Designated Customer,” “Designated Customer Baseline Amount,” “Designated Customer Baseline Year,” “Designated Customer Minimum Order Threshold” and “Threshold” as follows:

		
			“Baseline Amount” means [* *] gallons of Concentrate Products, which represents total orders in gallons for the year ended December 31, 2016, excluding the Designated Customer. 
		

		
			“Calendar Year” means a year ending December 31.
		

		
			“Designated Customer” means [* *]
		

		
			“Designated Customer Baseline Amount” means the total amount of gallons of Concentrate Products ordered during the Designated Customer Baseline Year by (i) Designated Customer (or its Affiliate if such Affiliate has executed such new contract) or (ii) the Distributor, its Affiliates, Marketing Partners, sub-distributors or otherwise for sale or transfer to the Designated Customer (or its Affiliate if such Affiliate has executed such new contract). 
		

		
			“Designated Customer Baseline Year” means the first full Calendar Year following the year in which the Designated Customer’s Original Customer Contract is assigned to Distributor or in which Distributor enters into a new contract for Concentrate Products with the Designated Customer (or its Affiliate if such Affiliate has executed such new contract instead of the Designated Customer). 
		

		
			“Designated Customer Minimum Order Threshold” has the meaning set forth in Section 3.8(a).
		

		
			

		 

		

			8

		

 

		

		
			“Threshold” means each of the Minimum Order Threshold and the Designated Customer Minimum Order Threshold and “Thresholds” means the Minimum Order Threshold and the Designated Customer Minimum Order Threshold, together.
		

			
	
			
				 10.
			Exhibit C of the Agreement is hereby amended by the following paragraph at the end thereof:

		
			Allocation
		

		
			To the extent that the cost of Transportation Services must be allocated between orders relating to the Designated Customer and other customers, such costs shall be allocated based upon the ratio of the weight of Concentrate Products sold to the Designated Customer compared to the weight of Concentrate Products sold to other customers, effective January 1, 2017. To the extent that the cost of Customer Services must be allocated between orders relating to the Designated Customer and other customers, such costs shall be allocated based upon the number of orders of Concentrate Products by the Designated Customer compared to the number of orders of Concentrate Products by Distributor for other customers, effective January 1, 2017.
		

			
	
			
				 11.
			Exhibit J of the Agreement is hereby amended by amending and restating the section entitled “Target Margins – Concentrate Products” as follows:

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Target Margins – Concentrate Products

				
	
					
						 

					
					
						Target Margin

				
	
					
						Year

					
					
						[* *]    

					
					
						  [* *] and [* *]  

					
					
						Other Domestic 

				
	
					
						2014

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2015

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2016

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2017

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2018

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2019

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2020

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2021

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2022

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2023

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2024

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2025

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2026

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2027

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2028

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				
	
					
						2029

					
					
						[* *]%

					
					
						[* *]%

					
					
						[* *]%

				

		
			*  Effective as of date of First Amendment.
		

		
			For purposes of this Exhibit J, “[* *]” means [* *] and “[* *]” means [* *].
		

		
			

		 

		

			9

		

 

		

			
	
			
				 12.
			Governing Law.  All issues and questions concerning the construction, validity, enforcement, and interpretation of this First Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the laws of the State of Delaware. 

			
	
			
				 13.
			No Other Changes.  Except as expressly modified in this First Amendment, all other terms and conditions of the Agreement remain unchanged and in full force and effect and shall govern and apply to all matters contemplated by this First Amendment.

			
	
			
				 14.
			Interpretation.  The term “Agreement” as used herein shall mean the Agreement as amended, modified, and supplemented by this First Amendment and all other capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.  

			
	
			
				 15.
			Counterparts and Facsimile/PDF Signatures.  This First Amendment may be executed in any number of counterparts, each of which when executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument.  The parties hereto agree that facsimile transmission or PDF of original signatures shall constitute and be accepted as original signatures.

			
	
			
				 16.
			Severability.  In the event that any provision of this First Amendment shall be held to be invalid or unenforceable in any respect, such provision shall be enforced to the fullest extent permitted by law and the remaining provisions of this First Amendment shall remain in full force and effect.  If any such invalid portion constitutes a material term of this First Amendment, the parties hereto shall meet and in good faith seek to mutually agree to modify this First Amendment so as to retain, if possible, the overall essential terms of this First Amendment.

		
			[SIGNATURE PAGE FOLLOWS]
		

		
			 
		

		
			

		 

		

			10

		

 

IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed by their duly authorized representatives and effective as of the date first above written.  
		

			
					
						 

					
					
						 

				
	
					
						COMPANY:

					
					
						DISTRIBUTOR:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						ROCKWELL MEDICAL, INC. 

					
					
						BAXTER HEALTHCARE CORPORATION

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:  

					
					
						/s/ Robert Chioini

					
					
						 

					
					
						By:  

					
					
						/s/ Gavin Campbell

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Print Name:  

					
					
						Robert Chioini

					
					
						 

					
					
						Print Name:  

					
					
						Gavin Campbell

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Title:  

					
					
						Chief Executive Officer

					
					
						 

					
					
						Title:  

					
					
						General Manager, US Renal

				

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		 

		

			11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]